Observational study to assess intravitreal aflibercept injections used in a “treat and extend” regimen in treatment-naïve wet age-related macular degeneration patients (ASTERIA)
The purpose of this observational study lies in the analysis of a treat-and-extend injection scheme with intravitreal aflibercept (i.e. injection into the eye), as applied in routine practice in previously untreated patients diagnosed with wet age-related macular degeneration.
- Diagnosis of wet age-related macular degeneration. - No prior therapy for wet age-related macular degeneration. - Patients for whom the decision to initiate treatment with IVT-AFL in a T&E regimen was made as per routine clinical practice. - Patient age >55 years of age
- Participation in an investigational program with therapeutical interventions outside of clinical routine practice. - Patients with eye diseases e.g. advanced glaucoma or visually significant cataracts, likely to require surgery during the observation period in the study eye. - Concomitant ocular or systemic administration of drugs up to 3 months before commencement of IVT-AFL treatment that could interfere with or potentiate the mechanism of action of aflibercept, including anti-VEGF agents. This includes patients receiving a different anti-VEGF agent for the fellow eye
Many Locations, Switzerland
E-mail: [email protected]
Phone: (+) 1-888-8422937
An observational study to assess the use of intravitreal aflibercept injections in a routine “treat and extend” regimen in treatment-naïve patients diagnosed with wet age-related macular degeneration